Loading...
A phase I pharmacokinetic and pharmacodynamic study of the oral mitogen-activated protein kinase kinase (MEK) inhibitor, WX-554, in patients with advanced solid tumours.
Jamieson, D Griffin, M Sludden, J Drew, Y Cresti, N Swales, K Merriman, M Allen, R Bevan, P Buerkle, M
Jamieson, D
Griffin, M
Sludden, J
Drew, Y
Cresti, N
Swales, K
Merriman, M
Allen, R
Bevan, P
Buerkle, M
Citations
Altmetric:
Abstract
We performed a multi-centre phase I study to assess the safety, pharmacokinetics (PK) and pharmacodynamics (PD) of the orally available small molecule mitogen-activated protein kinase kinase (MEK) 1/2 inhibitor, WX-554, and to determine the optimal biological dose for subsequent trials.
Description
Date
2016-09-28
Publisher
Collections
Files
Loading...
From UNPAYWALL
Adobe PDF, 2.33 MB
Keywords
Type
Article
Citation
A phase I pharmacokinetic and pharmacodynamic study of the oral mitogen-activated protein kinase kinase (MEK) inhibitor, WX-554, in patients with advanced solid tumours. 2016, 68:1-10 Eur. J. Cancer